ORIC Pharmaceuticals (FRA:4TZ) Tariff Resilience Score: 8/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4TZ ORIC Pharmaceuticals Inc FRA:4TZ
32 GF Score
Price €9.06
! 3 Warning Signs
View Full Analysis

What is ORIC Pharmaceuticals Tariff Resilience Score?

ORIC Pharmaceuticals FRA:4TZ +1.89% 32 Tariff Resilience Score is 8 as of Jul. 15, 2026. GuruFocus rates FRA:4TZ with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,370 Biotechnology companies, ORIC Pharmaceuticals ranks better than 98.69% on this metric.

ORIC Pharmaceuticals has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

ORIC Pharmaceuticals has Pharmaceutical company with a focus on domestic R&D and production. Limited exposure to tariffs due to the nature of its business and strong domestic market focus.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes ORIC Pharmaceuticals might have Highly Resilient.

ORIC Pharmaceuticals  (FRA:4TZ) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

ORIC Pharmaceuticals Tariff Resilience Score Related Terms

FRA:4TZ vs DRTS, OLMA, KURA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, ORIC Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ORIC Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's Tariff Resilience Score falls into.


FRA:4TZ
32GF Score
ORIC Pharmaceuticals Inc FRA:4TZ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
ORIC Pharmaceuticals (FRA:4TZ) has a Tariff Resilience Score of 8 as of Jul. 15, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, ORIC Pharmaceuticals ranks #18 out of 1370 companies in the Biotechnology industry, placing it in the top 1.3%.
Is ORIC Pharmaceuticals' Tariff Resilience Score too high?
ORIC Pharmaceuticals' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. ORIC Pharmaceuticals' value of 8 is 100% above this industry median. Based on the distribution chart, ORIC Pharmaceuticals ranks #18 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ORIC Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does ORIC Pharmaceuticals' Tariff Resilience Score compare to DRTS and OLMA?
According to the Biotechnology industry distribution chart, ORIC Pharmaceuticals ranks #18 out of 1370 companies for Tariff Resilience Score. This places ORIC Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. ORIC Pharmaceuticals' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ORIC Pharmaceuticals's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ORIC Pharmaceuticals's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ORIC Pharmaceuticals stock overvalued right now?
ORIC Pharmaceuticals (FRA:4TZ) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. ORIC Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For ORIC Pharmaceuticals (FRA:4TZ), the current Tariff Resilience Score is 8 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ORIC Pharmaceuticals Business Description

Other Exchanges ORIC:USA
Address 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
32GF Score

Get the complete analysis for FRA:4TZ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.06
Price